The Road Ahead: An Update on Investigational Agents and Strategies for HCV Management

In this interactive program, Raymond T. Chung, MD, reviews current challenges with HCV therapies, describes novel classes of anti-HCV agents and their anticipated benefits for patients, and walks through a series of cases designed to evaluate the question of treating now vs waiting for future HCV therapies.
Raymond T. Chung, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: December 12, 2012 Expiration: December 11, 2013

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the various classes of HCV agents and their targets
  • Appraise the emerging data on investigational agents for hepatitis C to assess the potential use in current practice
  • Apply appropriate treatment decisions based on individual patient factors and available HCV agents
  • Discuss current treatment options and emerging data on investigational HCV agents with patients

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Raymond T. Chung, MD

Director of Hepatology and Liver Center
Vice Chief,
Gastroenterology
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Raymond T. Chung, MD, has disclosed that he has received grants for research support from Gilead Sciences and Mass Biologic.

Staff

Jennifer M. Blanchette, PhD

Associate Managing Editor

Jennifer Blanchette, PhD, has no significant financial relationships to disclose.
Edward King, MA

Chief Innovation Officer

Edward King, MA, has no significant financial relationships to disclose.
Jenny Schulz, PhD

Senior Managing Editor

Jenny Schulz, PhD, has no significant financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP; Patricia Staples, MSN, NP-C, CCRN and Eric D. Peterson, EdM, FACEHP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians and other healthcare providers caring for patients with chronic hepatitis C.

Goal

The goal of this activity is to equip participants to critically assess data from studies of investigational agents for HCV to understand how these data affect patient management today and in the future.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 12, 2012, through December 11, 2013:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Audio from CCO faculty Dr. Nancy Reau on strategies to address gaps in viral hepatitis care: learn how to prevent HAV and HBV, how to screen for and treat HCV

Nancy Reau, MD Released: December 3, 2019

Downloadable slides on data from AALSD 2019 selected by expert faculty as relevant to care of patients with viral hepatitis or NAFLD/NASH, as reported by Clinical Care Options.

Ira M. Jacobson, MD Nancy Reau, MD Released: December 2, 2019

Downloadable slides from CCO and Dr. Nancy Reau on addressing gaps in viral hepatitis care: expert tips on managing HAV, HBV, HCV and on new AASLD guidance

Nancy Reau, MD Released: November 25, 2019

Clinical Care Options’ (CCO) expert audio analysis of new viral hepatitis data from AASLD 2019, provided by Norah Terrault, MD, MPH

Norah Terrault Headshot Norah Terrault, MD, MPH Released: November 22, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?